New Products Push Influenza Vaccine Market Above $3billion

A new report out from Kalorama Information estimates that influenza vaccines sales rose by 13% to $3.1 billion in 2013. This figure brings the influenza vaccines market up from $2.8 billion in 2012, and back to the sort of levels we saw before the government’s stockpiling 2010 -as a result of this stockpiling, and perhaps over purchasing, the market dropped …

Pfizer Presents Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults Evaluating Efficacy Of Prevenar 13*

Study Findings, Presented at ISPPD, Demonstrate that Prevenar 13 Can Prevent Vaccine-Type Community-Acquired Pneumonia March 12, 2014 Pfizer Inc. today presented detailed results of the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the landmark study of approximately 85,000 subjects, demonstrating that Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) prevented a first episode of vaccine-type community-acquired pneumonia (CAP) in adults 65 …

CDC Publishes 2014 Immunization Schedule

The Center for Disease Control and Prevention (CDC) have released their updated vaccination recommendations for adults of 19 years and above, having been approved back in October by a series of associations -including the Advisory Committee on Immunization, American Academy of Family Physicians, and the American College of Nurse-Midwives. By way of introduction to the schedule the CDC not the …

Pfizer unveil results of Prevnar 13 Phase 3 study in adults with HIV

Pfizer have unveiled the results from a Phase 3 study that trialled pneumococcal vaccine Prevnar 13 in adults infected with human immunodeficiency virus (HIV). In the Phase 3, open-label, single-arm trial, 331 HIV-infected individuals aged 18 years and older who had previously received at least one dose of pneumococcal polysaccharide vaccine (PSSV) were given three doses of Prevnar 13 at …

Climate change in vaccine trials: Moving from a one-size-fits-all to a custom fit in operational delivery

Dr Vigdorth has 30 years of drug development research experience in the clinical setting and pharmaceutical and CRO industries. She has led clinical development programs across a range of therapeutic indications with extensive experience in antibiotic, antiviral, vaccine, and antifungal agents.   Dr Vigdorth's experience has developed from multiple perspectives including working in the clinical investigative site setting, multi- national …